Shanghai, China

Shengqin Ye

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 5.3

ph-index = 1


Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Shengqin Ye in CAR-T Cell Technology

Introduction

Shengqin Ye is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of CAR-T cell therapies. With a total of 3 patents, his work focuses on enhancing the efficacy of cancer treatments through innovative cellular technologies.

Latest Patents

One of Shengqin Ye's latest patents is titled "Universal CAR-T cell and preparation method and use thereof." This invention discloses a universal CAR-T cell that knocks out one or more of CD3 delta, CD3 gamma, CD3 epsilon, and CD3 zeta, while simultaneously introducing the HSV-TK gene. The patent also details a method for preparing this CAR-T cell, along with its applications in therapeutic settings.

Another significant patent is "Chimeric antigen receptor comprising co-stimulatory receptor and application thereof." This invention provides a chimeric antigen receptor that includes a co-stimulatory receptor, designed to enhance the tumor-killing abilities of CAR-T cells. The structure of the receptor is defined as scFv(X)-(Y)CD3zeta-2A-(Z), where X represents a tumor-targeting antibody or a ligand capable of binding specifically to a tumor. The invention also outlines the construction of CAR-T cells using a recombinant expression vector of the described chimeric antigen receptor.

Career Highlights

Shengqin Ye is currently associated with Shanghai Longyao Biotechnology Inc., Ltd., where he continues to innovate in the field of biotechnology. His work has been instrumental in advancing CAR-T cell therapies, which hold promise for treating various types of cancer.

Collaborations

Shengqin Ye collaborates with notable colleagues, including Xuanming Yang and Yangxin Fu. Their combined expertise contributes to the ongoing research and development efforts in the field of CAR-T cell technology.

Conclusion

Shengqin Ye's contributions to CAR-T cell technology exemplify the potential of innovative approaches in cancer treatment. His patents reflect a commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…